Adriamycin(hydrazone)-antibody conjugates require internalization and intracellular acid hydrolysis for antitumor activity

SummaryAdriamycin hydrazone (ADM-Hzn) immunoconjugates have previously been shown to exhibit antibody-directed antitumor activity in vitro and in vivo. In this report, the biological and biochemical properties of the mAb and linker were investigated. Conjugates prepared with two antibodies 5E9 [anti-(transferrin receptor)] and G28.1 (anti-CD37), (which internalize from the surface of target cells following binding) were more cytotoxic in vitro and had greater antitumor activity against Daudi B lymphoma tumor xenografts than a non-internalizing immunoconjugate prepared with mAb 2H7 (anti-CD20). In addition, the 13-acylhydrazone bond linking the drug to the mAb was labile at pH 5 and released unmodified ADM at a rapid rate (t1/2 = 2.5 h). Immunoconjugates prepared with an oxime linkage at the C-13 position were stable to acid and were not cytotoxic. These findings suggest that internalization of ADM-Hzn immunoconjugates and release of free ADM from the mAb in acidic intracellular compartments were important steps in the mechanism of action of ADM-Hzn immunoconjugates.

[1]  R. Webb,et al.  Synthesis of 1-(aminooxy)-4-[(3-nitro-2-pyridyl)dithio]butane and 1-(aminooxy)-4-[(3-nitro-2-pyridyl)dithio]but-2-ene, novel heterobifunctional cross-linking reagents. , 1990, Bioconjugate chemistry.

[2]  R. W. Baldwin,et al.  Endocytosis of a monoclonal antibody recognising a cell surface glycoprotein antigen visualised using fluorescent conjugates. , 1986, European journal of cell biology.

[3]  T. Kaneko,et al.  Evaluation in vitro of adriamycin immunoconjugates synthesized using an acid-sensitive hydrazone linker. , 1990, Cancer research.

[4]  J. Marsh Antibody-mediated routing of diphtheria toxin in murine cells results in a highly efficacious immunotoxin. , 1988, The Journal of biological chemistry.

[5]  R. Reisfeld,et al.  Rate of internalization of an immunotoxin correlates with cytotoxic activity against human tumor cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[6]  I. Witz,et al.  Receptors for immune complexes on cells within a polyoma virus‐induced murine sarcoma , 1976, European journal of immunology.

[7]  T. Kaneko,et al.  Antitumor activity of adriamycin (hydrazone-linked) immunoconjugates compared with free adriamycin and specificity of tumor cell killing. , 1990, Cancer research.

[8]  R. Reisfeld,et al.  Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[9]  R. W. Baldwin,et al.  Studies on the mechanism of action of an antibody-targetted drug-carrier conjugate. , 1985, Anti-cancer drug design.

[10]  P. Casellas,et al.  Endocytosis of an antibody ricin A-chain conjugate (immuno-A-toxin) adsorbed on colloidal gold. Effects of ammonium chloride and monensin. , 1985, Experimental cell research.

[11]  S. Order,et al.  Radiolabeled antibodies: results and potential in cancer therapy. , 1990, Cancer research.

[12]  S. Gawlak,et al.  Optimization of immunotherapy with adriamycin(hydrazone)-immunoconjugates in human B-lymphoma xenografts , 1991 .

[13]  J. Koziol,et al.  Superiority of an acid-labile daunorubicin-monoclonal antibody immunoconjugate compared to free drug. , 1988, Cancer research.

[14]  E. Lavie,et al.  Evaluation of L6, an anti-carcinoma murine monoclonal antibody, in tumor-bearing nude mice. , 1989, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[15]  L. Huang,et al.  Interactions of immunoliposomes with target cells. , 1983, The Journal of biological chemistry.

[16]  I. Witz,et al.  Tumor bound immunoglobulins: The relationship between the in vivo coating of tumor cells by potentially cytotoxic anti‐tumor antibodies, and the expression of immune complex receptors , 1976, International journal of cancer.

[17]  F. Preijers,et al.  Relationship between internalization and cytotoxicity of ricin A‐chain immunotoxins , 1988, British journal of haematology.

[18]  R D Klausner,et al.  Exposure of K562 cells to anti-receptor monoclonal antibody OKT9 results in rapid redistribution and enhanced degradation of the transferrin receptor , 1986, The Journal of cell biology.

[19]  I. Witz The biological significance of tumor-bound immunoglobulins. , 1973, Current topics in microbiology and immunology.

[20]  G. Yee,et al.  The anticancer agent adriamycin can be actively cytotoxic without entering cells. , 1982, Science.

[21]  I. Witz,et al.  Receptors for immune complexes on cells within a non-lymphoid murine tumor. , 1976, Journal of immunology.

[22]  Mastrangelo Mj,et al.  Serotherapy of cancer. , 1989 .

[23]  E. Vitetta,et al.  Ricin A-chain containing immunotoxins directed against different epitopes on the CD2 molecule differ in their ability to kill normal and malignant T cells. , 1988, Journal of immunology.

[24]  R. W. Baldwin,et al.  Preparation and properties of a drug‐carrier‐antibody conjugate showing selective antibody‐directed cytotoxicity in vitro , 1983, International journal of cancer.

[25]  Baldwin Rw,et al.  Endocytosis of a monoclonal antibody recognising a cell surface glycoprotein antigen visualised using fluorescent conjugates. , 1986 .

[26]  D. Johnson,et al.  Mechanisms of human CD5 modulation and capping induced by murine monoclonal antibody T101. , 1988, Clinical immunology and immunopathology.

[27]  R. Steinman,et al.  Endocytosis and the recycling of plasma membrane , 1983, The Journal of cell biology.

[28]  S. Larson Clinical radioimmunodetection, 1978-1988: overview and suggestions for standardization of clinical trials. , 1990, Cancer research.

[29]  J. Ritz,et al.  Monoclonal antibody-ricin A chain conjugate selectively cytotoxic for cells bearing the common acute lymphoblastic leukemia antigen. , 1982, Cancer research.

[30]  C. Hopkins,et al.  Internalization and processing of transferrin and the transferrin receptor in human carcinoma A431 cells , 1983, The Journal of cell biology.